retatrutide peptide clinical trial ESC 2024: improves lipid and cardiovascular risk profile in Phase II Retatrutide Online | Simple Online

By combining three receptor targets into a single molecule, researchers aim to achieve enhanced reduction of weight, improved blood glucose control, and potentially greater metabolic flexibility compared to earlier therapies

Berenbaum, F., Bougault, C

Why GLP-1 Treatments May Cause Hair Thinning The mechanism behind hair loss in patients taking GLP-1 medications is not directly related to the drug's pharmacological action on GLP-1 receptors

Vi kan inte alltid tillmtesg en sdan begran, speciellt om vi fortfarande behver uppgifterna fr ett pgende avtal eller om lagstiftningen krver att vi behller vissa uppgifter

In TRIUMPH-4 (obesity + knee OA): nausea 43%, diarrhea 33%, vomiting 21%, constipation 25%, dysesthesia 20.9%

GLP-1-based therapies for diabetes, obesity and beyond